# Phase 2 Study Comparing Two Dose Schedules of Telintra™ in Myelodysplastic Syndrome (MDS)

> **NCT00700206** · PHASE2 · COMPLETED · sponsor: **Telik** · enrollment: 86 (estimated)

## Conditions studied

- Myelodysplastic Syndrome (MDS)

## Interventions

- **DRUG:** Ezatiostat Hydrochloride

## Key facts

- **NCT ID:** NCT00700206
- **Lead sponsor:** Telik
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-05
- **Primary completion:** 2011-07
- **Final completion:** 2011-07
- **Target enrollment:** 86 (ESTIMATED)
- **Last updated:** 2011-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00700206

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00700206, "Phase 2 Study Comparing Two Dose Schedules of Telintra™ in Myelodysplastic Syndrome (MDS)". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT00700206. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*